Liberum Capital Reaffirms “Buy” Rating for GlaxoSmithKline (LON:GSK)


Share on StockTwits

GlaxoSmithKline (LON:GSK)‘s stock had its “buy” rating restated by research analysts at Liberum Capital in a note issued to investors on Thursday, Price Targets.com reports. They currently have a GBX 1,700 ($22.21) price target on the stock. Liberum Capital’s price target indicates a potential upside of 26.26% from the stock’s previous close.

A number of other brokerages have also recently commented on GSK. Berenberg Bank decreased their price objective on GlaxoSmithKline from GBX 1,720 ($22.47) to GBX 1,570 ($20.51) and set a “buy” rating for the company in a research note on Thursday, February 11th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 1,925 ($25.15) target price on shares of GlaxoSmithKline in a research note on Tuesday, February 9th. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline in a research note on Tuesday, January 26th. Oddo Bhf set a GBX 1,490 ($19.47) target price on GlaxoSmithKline and gave the company a “neutral” rating in a research note on Thursday, February 4th. Finally, The Goldman Sachs Group set a GBX 1,820 ($23.78) target price on GlaxoSmithKline and gave the company a “buy” rating in a research note on Tuesday, March 16th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of GBX 1,536.21 ($20.07).

GSK opened at GBX 1,346.40 ($17.59) on Thursday. The firm has a market capitalization of £67.74 billion and a P/E ratio of 11.80. The stock’s 50 day moving average price is GBX 1,272.96 and its two-hundred day moving average price is GBX 1,345.03. The company has a quick ratio of 0.62, a current ratio of 0.91 and a debt-to-equity ratio of 130.48. GlaxoSmithKline has a 12-month low of GBX 1,190.80 ($15.56) and a 12-month high of GBX 1,748.55 ($22.84).

In other GlaxoSmithKline news, insider Urs Rohner acquired 619 shares of the company’s stock in a transaction on Wednesday, February 3rd. The shares were purchased at an average price of GBX 1,361 ($17.78) per share, for a total transaction of £8,424.59 ($11,006.78). Also, insider Emma Walmsley sold 32,346 shares of the company’s stock in a transaction that occurred on Monday, March 1st. The shares were sold at an average price of GBX 1,211 ($15.82), for a total value of £391,710.06 ($511,771.70). Insiders acquired 638 shares of company stock worth $866,798 in the last 90 days.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Read More: What is a management fee?

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.